Operating Income: The income after operating expenses.
Urogen Pharma (URGN) had Operating Income of $-27.39M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$27.48M |
|
$-33.35M |
|
$3.28M |
|
$24.20M |
|
$54.87M |
|
|
Operating Income |
$-27.39M |
$-7.01M |
|
$-34.40M |
|
$-34.40M |
|
$-33.35M |
|
$-33.35M |
|
$-33.35M |
|
$-33.35M |
|
$-27.39M |
|
$-27.47M |
|
48.06M |
|
48.06M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$168.55M |
|
$0.69M |
|
$16.50M |
|
$185.05M |
|
$42.24M |
|
$122.11M |
|
$258.21M |
|
$300.45M |
|
$-115.41M |
|
$-115.41M |
|
$-115.41M |
|
46.78M |
|
| Cash Flow Statement Financials | |
$-124.12M |
|
$33.84M |
|
$8.60M |
|
$173.06M |
|
$91.39M |
|
$-81.68M |
|
$8.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.99 |
|
-- |
|
-- |
|
18.22 |
|
-1.06 |
|
88.07% |
|
-99.65% |
|
-99.65% |
|
-- |
|
-125.18% |
|
-121.34% |
|
$-124.39M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.39 |
|
1.39 |
|
64.52 |
|
28.89% |
|
28.89% |
|
-18.02% |
|
-497.49% |
|
$-2.47 |
|
$-2.59 |
|
$-2.58 |
|